Alvogen Pine Brook LLC et al. vs Celgene Corporation

Notice of Refund

Petitioner's Request for Refund of Post-Institution Fees

Trial Instituted Document

Patent Owner Preliminary Response

Ex. 2003 (Hatch Act)

Ex. 2005 (Barker)

Ex. 2007 (Fishman)

Ex. 2001 (Hideshima 2008)

Ex. 2002 (August 2018 Guide)

Ex. 2004 (Merck)

Ex. 2006 (Lynch)

Ex. 2008 (File History Excerpt)

Ex. 2009 (Marriott 2002)

Ex. 2010 (Zangari 2001)

Ex. 2011 (Zangari 2003)

Ex. 2013 (Remes)

Ex. 2014 (Barlogie 1991)

Ex. 2012 (Gordon)

Ex. 2015 (Harousseau et al 1992)

Ex. 2016 (Lokhorst et al 1992)

Ex. 2017 (Troussard)

Ex. 2019 (Goudarzipour et al 2013)

Ex. 2018 (Weick 2002)

Patent Owner's Mandatory Notices

Patent Owner Power of Attorney

Notice of Accord Filing Date

Petition for Inter Partes Review of US Patent No. 7,968,569

Power of Attorney

Sampaio et al., "Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes," J. Exp. Med., 173(3): 699-703 (1991).

Tramontana et al., "Thalidomide Treatment Reduces Tumor Necrosis Factor ¿¿ Production and Enhances Weight Gain in Patients with Pulmonary Tuberculosis," Molecular Medicine, 1:384-397 (1995)

Singhal et al., "Antitumor Activity of Thalidomide in Refractory Multiple Myeloma," N. Engl. J. Med., 341:1565-1571 (1999)

Durie & Stepan, "Efficacy of Low Dose Thalidomide in Multiple Myeloma," Electronic Journal of Oncology, 1:1-8 (2000).

U.S. Patent No. 7,968,569 ("the '569 patent")

Prosecution History excerpts for U.S. Patent No. 7,968,569

Expert Declaration of Dr. Guido Tricot

Muller et al., "Amino-substituted Thalidomide Analogues: Potent Inhibitors of TNF-¿¿ Productions," Bioorganic & Medicinal Chemistry Letters, 9:1625-1630 (1999).

Corral et al., "Differential Cytokine Modulation and T Cell Activation by Two Distinct Classes of Thalidomide Analogues That are Potent Inhibitors of TNF-¿¿," J. Immunol., 163: 380-386 (1999).

Corral & Kaplan, "Immunomodulation by thalidomide and thalidomide analogues," Ann. Rheum. Dis., 58: I107-I113 (1999).

Celgene Corp., Press Release, August 28, 2001.

Celgene Corp., "Celgene Corporation Receives Orphan Drug Designation for Revimid(TM) For Multiple Myeloma," October 8, 2001.

Hideshima, et al., "Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy," Blood, 96:2943-2950 (2000).

Enzinger et al., "Phase II clinical trial of 13-cis-retinoic acid and interferon-¿¿-2a in patients with advanced esophageal carcinoma," Cancer, 85:1213-1217 (1999).

Gebbia et al., "Single agent 2',2'-difluorodeoxycytidine in the treatment of metastatic urothelial carcinoma: a phase II study," La Clinica Terapeutica, 150(1):11-15 (1999).

Gordon et al., "A Phase I Trial of Recombinant Human Interleukin-11 (Neumega rhIL-11 Growth Factor) in Women With Breast Cancer Receiving Chemotherapy," Blood J., 87: 3615-3624 (1996).

Celesti et al., "The association of cyclophosphamide and dexamethasone in advanced refractory multiple myeloma patients," Haematologica, 82(3):351-353 (1997).

Imashuku et al., "Management of severe neutropenia with cyclosporin during initial treatment of Epstein-Barr virus-related hemophagocytic lymphohistiocytosis," Leuk. Lymphoma, 36(3-4):339-346 (2000).

Rajkumar & Kyle, "Thalidomide in the Treatment of Plasma Cell Malignancies," J. of Clinical Oncology, 19(16):3593-3595 (Aug. 2001).

Celgene Corp., Press Release, May 8, 2001.

Palumbo, et al, "Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma," Hematologica, 86(4):399-403 (April 2001).

V. T. DeVita, Jr., "Chapter 16: Principles of Chemotherapy," Cancer: Principles and Practice of Oncology, Fourth Edition (1993).

Jacobs et al., "Prednisone in MOPP chemotherapy for Hodgkin's disease," Br. Med. J., 2:1469-1471 (1976).

Koo et al., "Vancomycin-induced neutropenia," Drug Intell. Clin. Pharm., 20(10):780-782 (1986).

Cytovene¿¿-IV, Physicians' Desk Reference 2623-2629 (54th ed. 2000)

Revlimid Label

Parameswaran et al., "CCNU (lomustine), idarubicin and dexamethasone (CIDEX): an effective oral regimen for the treatment of refractory or relapsed myeloma," Br. J. Haematol., 109(3):571-575 (2000).

Pomalyst Label

U.S. Patent No. 6,281,230 ("the '230 Patent")

Marisavljevic et al., "Results of treatment of patients with advanced multiple myeloma with the vincristine-adriamycin-dexamethasone protocol," Srp Arh Celok Lek, 124(11-12):292-296 (1996).

Rajkumar, S.V., et al., "Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma," Blood, 106:4050-4053 (2005)

Gay, F., et al., "Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients," Blood, 115:1343-1350 (2010)

Weber, D., et al., "Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America," N. Engl. J. Med. 357(21):2133-2142 (2007)

Palumbo, A., et al., "Lenalidomide: A new therapy for multiple myeloma," Cancer Treatment Reviews 34:283-291 (2008)

Dimopoulos, M.A., et al., "Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma," Leukemia 23:2147-2152 (2009)

Gandhi, A.K., "Dexamethasone Synergizes with Lenalidomide to Inhibit Multiple Myeloma Tumor Growth, But Reduces Lenalidomide-Induced Immunomodulation of T and NK Cell Function," Curr. Cancer Drug Targets, 10:155-167 (2010)

Malpas, "Management of Multiple Myeloma," Br Med J., 2:163-165 (1969)

Palmer et al., "Dose Intensity Analysis of Melphalan and Prednisone in Multiple Myeloma" J Natl Cancer Inst, 80:414-418 (1988)

Oken et al., "Contribution of Prednisone to the Effectiveness of Hexamethylmelamine in Multiple Myeloma," Cancer Treatment Reports, 71:807-811 (1987)

Bell et al., "Chapter 5. The Hematopoietic System and Development of Blood Cells," The Johns Hopkins Atlas of Human Functional Anatomy, 4th ed. 1997

Bilgrami et al., "Dexamethasone, paclitaxel, etoposide, cyclophosphamide (d-TEC) and G-CSF for stem cell mobilisation in multiple myeloma," Bone Marrow Transplantation, 28:137-143 (July 2001).

Moreira et al., "Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation," J Exp Med., 177:1675-1680 (1993)

Barlogie et al., "Effective treatment of advanced multiple myeloma refractory to alkylating agents," N Engl J Med., 310(21):1353-1356 (1984).

Browman et al., "Modified adriamycin-vincristine-dexamethasone (m-VAD) in primary refractory and relapsed plasma cell myeloma: an NCI (Canada) pilot study," Br. J. Haematol., 82(3):555-559 (1992).

J. Blade and J. Esteve, "Treatment Approaches for Relapsing and Refractory Multiple Myeloma," Acta Oncologica, 39(7):843-847 (2000).

Dimopoulos, M., et al., "Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma," N. Engl. J. Med. 357(21):2123-2132 (2007)

Lacy, M.Q., et al., "Long-term Results of Response to Therapy, Time to Progression, and Survival With Lenalidomide Plus Dexamethasone in Newly Diagnosed Myeloma," Mayo Clin. Proc. 82(10):1179-1184 (2007)

Armoiry, X., et al., "Lenalidomide in the treatment of multiple myeloma: a review," J. Clin. Pharm. Ther. 33:219-226 (2008)

Morgan J. et al., "Overall survival with dexamethasone in phase III multiple myeloma trials after adjustment for cross-over to lenalidomide," Haematologica 93(s1), Abstract 0441 (2008)

Gennaro, A., Remington: The Science and Practice of Pharmacy, 20th Edition (2000)

U.S. Provisional Application No. 60/380,842

Affidavit of Christopher Butler, Internet Archive

Declaration of James L. Mullins, Ph.D. (Part 1 of 5)

Declaration of James L. Mullins, Ph.D. (Part 2 of 5)

Declaration of James L. Mullins, Ph.D. (Part 3 of 5)

Declaration of James L. Mullins, Ph.D. (Part 5 of 5)

U.S. Food and Drug Administration, "List of Orphan Designations and Approvals," available at https://www.accessdata.fda.gov/scripts/opdlisting/oopd/ (published online and in print October 2001)

Barlogie et al., "Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients," Blood 98(2):492-494 (July 2001)

Declaration of James L. Mullins, Ph.D. (Part 4 of 5)

21 C.F.R. 300-499 (as of April 1, 2001)

Lotus Pharmaceutical Co., Ltd. and Alvogen Pine Brook LLC's First Set of Requests for Admission (Nos. 1-3)

Lotus Pharmaceutical Co., Ltd. and Alvogen Pine Brook LLC's First Set of Interrogatories (Nos. 1-31)

Malpas and Rohatiner, "Principles of Cancer Chemotherapy," Advances in Oncology 1:317-350 (1996)

Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, Patent and Exclusivity for: N021880